Sorafenib (Nexavar)
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
neurofibromatosis1 (NF1)
Conditions
neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
Trial Timeline
Apr 1, 2011 → Mar 1, 2013
NCT ID
NCT01338857About Sorafenib (Nexavar)
Sorafenib (Nexavar) is a phase 2 stage product being developed by Bayer for neurofibromatosis1 (NF1). The current trial status is terminated. This product is registered under clinical trial identifier NCT01338857. Target conditions include neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01338857 | Phase 2 | Terminated |